S)-2-(8-Amino-1-Bromo-Imidazo[1,5-A]Pyrazin-3-Yl)-Pyrrolidine-1-Carboxylic Acid Benzyl Ester

In the manufacturing environment for covalent Bruton's tyrosine kinase (BTK) inhibitors, the chiral integrity of the pyrrolidine substructure governed by (S)-2-(8-Amino-1-Bromo-Imidazo[1,5-A]Pyrazin-3-Yl)-Pyrrolidine-1-Carboxylic Acid Benzyl Ester becomes a critical control point. The benzyl carbamate protecting group is retained through transition-metal-mediated cross-coupling steps, surviving Suzuki-Miyaura conditions that install biaryl motifs at the C-1 bromine position, with oxidative addition rates measured against Pd(dppf)Cl₂·CH₂Cl₂ (CAS 95464-05-4) in dioxane/water systems at 85–95°C. Manufacturers operating under ICH Q11 for starting material designation assign this intermediate a GMP step-forward boundary because the free 8-amino group is directly involved in the final API's hinge-binding pharmacophore, meaning any dimethylamine carryover from deprotection must be quantified below 0.15% by GC-headspace analysis per Ph. Eur. 2.4.24. The downstream process typically adds the compound at a stoichiometric ratio of 1.0–1.05 equivalents relative to the boronic acid coupling partner, charged after nitrogen sparging and held at a controlled moisture specification of KF ≤0.05% w/w to prevent catalyst poisoning. Subsequent hydrogenolysis over 10% Pd/C (Johnson Matthey type 87L) in THF/IPA mixtures cleaves the Cbz group, releasing the free secondary amine that is telescoped directly into acrylamide formation using acryloyl chloride under Schotten-Baumann conditions at 0–5°C, achieving the covalent warhead required for Cys481 targeting. The terminal drug substance belongs to the irreversible BTK inhibitor class, currently represented by ibrutinib analogues and next-generation candidates with improved selectivity profiles, where residual palladium below the 10 ppm oral PDE limit specified in EMA/CHMP/SWP/4446/2000 is verified by validated ICP-MS method on every campaign batch.

What Happens When the Bromine Atom Is Displaced Before the Amino Group Is Functionalized?

In phosphoinositide 3-kinase delta (PI3Kδ) inhibitor synthesis, inverted reaction sequencing—where the C-1 bromine undergoes amination prior to 8-amino derivatization—generates a problematic mixture of regioisomers that can only be resolved by preparative chiral SFC with a Chiralpak IG column (Daicel, 5 µm, 250 × 30 mm) at a cost of approximately 12–18 hours of instrument time per 100 g input. The preferred route therefore anchors the 8-aminoimidazo[1,5-a]pyrazine core with the bromine intact, coupling the pyrrolidine Cbz ester under Buchwald-Hartwig conditions using Pd₂(dba)₃ and Xantphos in toluene at 110°C with sodium tert-butoxide as base, where the benzyl ester's stability against β-hydride elimination of the pyrrolidine ring is monitored by in-situ ReactIR at 1745 cm⁻¹ (carbonyl stretch). The compound is charged at 0.95 equivalents relative to the amine donor to minimize palladium scavenging by excess ligand, and the crude coupling mixture is filtered through a Celite pad pre-wetted with 10% aqueous citric acid to remove palladium black before solvent exchange into dichloromethane for silica plug purification. Compliance with USP <232>/<233> elemental impurity limits for palladium (oral PDE 100 µg/day) and lithium (oral PDE 550 µg/day) is confirmed on isolated intermediate, as lithium chloride byproduct from the Buchwald-Hartwig quench partitions unpredictably into the organic phase when THF is present above 5% v/v. The final API incorporates a propynyl-substituted quinazolinone or indole scaffold linked through the 8-amino position, and the formulation is commonly developed as a hard gelatin capsule with micronized drug substance where D90 is controlled below 10 µm by jet milling under nitrogen to satisfy dissolution acceptance criteria at Q=80% in 30 minutes per USP <711> Apparatus II at 50 rpm in 0.1 M HCl.

Adeno-associated virus serotype 2 (AAV2) capsid modification chemistry has adopted this Cbz-pyrrolidine intermediate for the preparation of proteolysis-targeting chimeras (PROTACs) that recruit cereblon E3 ligase to non-structural viral proteins. The C-1 bromine undergoes Stille coupling with 2-tributylstannylpyridine derivatives in degassed DMF using Pd(PPh₃)₄ at 3 mol% loading, and strict exclusion of oxygen during the 16-hour reaction period is enforced because tin homocoupling generates dibutyltin oxide, which co-elutes with the desired product on silica gel at Rf 0.3–0.35 in ethyl acetate/hexane (1:1). The benzyl carbamate protecting group is deliberately preserved through this step because premature deprotection exposes a free pyrrolidine nitrogen that undergoes rapid N-arylation with excess stannane under the same catalytic conditions, leading to an impurity that crystallizes alongside the product in methylcyclohexane/MTBE mixtures unless controlled below 0.8 area% at the crude stage. The intermediate is used at 1.2 equivalents relative to a PEG4-alkyl linker bearing a terminal phthalimide masked glutarimide, acylation occurring at the 8-amino group of the imidazopyrazine with HATU and DIPEA in DMF at ambient temperature over 24 hours. After preparative HPLC purification on a C18 column with 0.1% TFA in water/acetonitrile mobile phase, the TFA salt is counterion-exchanged to the free base using Amberlyst A-21 resin in methanol. The final PROTAC molecule is formulated as a lyophilized powder containing trehalose dihydrate and polysorbate 20, reconstituted in water for injection, with subvisible particle counts maintained below 6000 particles per container (≥10 µm) and 600 particles per container (≥25 µm) per USP <787>. All intermediates bearing the Cbz group are stored under argon at −20°C ± 5°C with desiccant, as moisture ingress above 1000 ppm in headspace accelerates benzyl alcohol formation through carbamate hydrolysis, and benzyl alcohol is classified as an ICH Q3C Class 3 residual solvent with a permitted daily exposure limit of 50 mg/day.

A Convergent Route to Adaptor-Associated Kinase 1 Modulators via the C-1 Bromo Handle

In adaptor-associated kinase 1 (AAK1) inhibitor programs, the C-1 bromine atom on the imidazo[1,5-a]pyrazine scaffold functions as a synthetic handle for carbon-nitrogen bond formation with 4-aminopiperidine derivatives under a palladium-catalyzed system using BrettPhos Pd G3 precatalyst (CAS 1470372-59-8) and BrettPhos ligand (2.0 mol% each) in 2-methyltetrahydrofuran. The reaction is conducted at a concentration of 0.15 M with respect to the limiting aryl bromide, and the 1:1.05 stoichiometry between the intermediate and the amine coupling partner is maintained to within ±2% deviation because excess primary amine initiates reductive debromination that generates the des-bromo impurity, which is structurally similar enough to the product that it passes through the subsequent hydrogenolysis step and contaminates the final API as a Class 2-related substance according to ICH Q3A thresholds. The benzyl ester protecting group is removed via transfer hydrogenation using 1,4-cyclohexadiene as the hydrogen donor and 10% Pd/C (0.05 equiv) in ethanol at 60°C rather than by balloon hydrogenolysis, because the alkene acceptor suppresses over-reduction of the imidazo[1,5-a]pyrazine ring system observed under hydrogen gas atmospheres above 15 psi. The liberated pyrrolidine secondary amine is subsequently acylated with cyclopropanecarbonyl chloride in the presence of triethylamine in dichloromethane at −10°C to install the cyclopropylamide motif recognized by AAK1's DFG-out conformation. Final API batches intended for neuropathic pain indications are dried in a conical tumble dryer at 40°C jacket temperature and ≤5 mbar vacuum until residual 2-methyltetrahydrofuran drops below 500 ppm as measured by headspace GC-FID, referencing ICH Q3C limits where 2-MeTHF is a Class 3 solvent with PDE of 50 mg/day.

Diacylglycerol Acyltransferase 2: Hepatic Safety Margins and the Role of the Imidazopyrazine Amine

During scale-up of diacylglycerol acyltransferase 2 (DGAT2) inhibitors for non-alcoholic steatohepatitis, the 8-amino substituent on the imidazo[1,5-a]pyrazine core is acylated with a substituted phenylacetic acid derivative to form an amide linkage that occupies the acyl-CoA binding tunnel, and the benzyl carbamate on the pyrrolidine must be base-stable throughout this transformation because premature Cbz cleavage produces a pyrrolidine nitrogen that competes as a nucleophile, generating a bis-acylated dimer identified by LCMS as [M+H]⁺ = m/z 782.3. The acylation uses EDC hydrochloride and HOBt hydrate in acetonitrile/DMF (4:1) with N-methylmorpholine to maintain pH 7.5–8.0, and the intermediate is charged at 1.05 equivalents relative to the carboxylic acid after azeotropic drying with acetonitrile to KF ≤0.03% because residual water promotes O-acylisourea rearrangement to unreactive N-acylurea, reducing coupling efficiency below 55% as tracked by in-process HPLC at 254 nm. Following aqueous workup with 5% sodium bicarbonate and 1 M HCl washes, the organic phase is concentrated and the benzyl ester is removed by hydrogenation over 5% Pd/C (wet, Degussa type E101 N/D) in THF at atmospheric pressure, with endpoint detection by TLC (ninhydrin stain) confirming disappearance of the Cbz-protected spot at Rf 0.65. The free amine is subsequently converted to a methanesulfonamide by reaction with methanesulfonyl chloride (1.5 equiv) and pyridine in dichloromethane at 0°C, and the sulfonamide product is isolated as a crystalline hemihydrate after aqueous workup and recrystallization from ethyl acetate/heptane. Tablets are formulated by direct compression with microcrystalline cellulose (Avicel PH-102), croscarmellose sodium (3% w/w), and magnesium stearate (0.75% w/w) to a target hardness of 8–12 kp, with dissolution testing in 0.1 M HCl containing 0.5% sodium lauryl sulfate meeting a Q=80% at 45 minutes criterion per FDA dissolution guidance for BCS Class II weak bases.

Manufacture of pan-TRK (tropomyosin receptor kinase) inhibitors for solid tumors bearing NTRK gene fusions utilizes this intermediate at the stage where the C-1 bromine is displaced by a vinyl boronate ester under Suzuki coupling, and the 8-amino group has been previously protected with a transient trimethylsilylethoxymethyl (SEM) group to prevent catalyst coordination at the imidazopyrazine nitrogen atoms. The SEM protection is performed by treatment of the intermediate with SEM chloride (2.2 equiv) and sodium hydride (60% dispersion in mineral oil, 2.5 equiv) in DMF at 0°C to room temperature under nitrogen, and completion is confirmed by quenching an aliquot into methanol and observing the absence of the parent peak at [M+H]⁺ = m/z 416.1 by LCMS. The SEM-protected intermediate is telescoped into a Suzuki coupling with vinylboronic acid pinacol ester (1.3 equiv), PdCl₂(dppf)·CH₂Cl₂ (0.04 equiv), and 2 M aqueous potassium carbonate in DME at 85°C for 6 hours under nitrogen, followed by addition of Darco KB-G activated carbon (10 wt% relative to theoretical product) at 50°C with stirring for 2 hours before filtration through a Zeta Plus R53SP depth filter to reduce palladium to ≤10 ppm. The vinyl group is subsequently oxidized to the corresponding aldehyde using osmium tetroxide (2.5 mol%, as a 4% aqueous solution) and sodium periodate (4.0 equiv) in THF/water (3:1) at room temperature for 18 hours, and the aldehyde undergoes reductive amination with an appropriately substituted 4-aminopyrazole using sodium triacetoxyborohydride (1.8 equiv) and acetic acid (1.0 equiv) in 1,2-dichloroethane. SEM cleavage is achieved with 6 M HCl in isopropanol at 50°C, followed by pH adjustment to 8–9 with aqueous ammonia and extraction into ethyl acetate. The final Cbz deprotection via hydrogenolysis over 10% Pd/C in methanol at atmospheric hydrogen pressure yields the free pyrrolidine, which is immediately precipitated as the hydrochloride salt by addition of 1.25 M HCl in ethanol and diethyl ether, filtered under a nitrogen blanket, and dried in a vacuum oven at 35°C for 24 hours. This salt form is the penultimate intermediate for larotrectinib-class API, with enantiomeric purity verified at >99.5% ee by chiral HPLC on a Chiralpak AD-H column using hexane/isopropanol/diethylamine (80:20:0.1) mobile phase.

When the Cbz Ester Must Survive an Aqueous-Organic Biphasic Workup at Elevated pH

Development of cystic fibrosis transmembrane conductance regulator (CFTR) correctors in the bispyrazole-carboxamide series exploits the 1-bromo-8-amino substitution pattern on the imidazo[1,5-a]pyrazine to build a fused tricyclic core via an intramolecular Buchwald cyclization that constructs the central seven-membered lactam ring in a single pot. The intermediate is first N-alkylated at the 8-amino position with methyl 4-bromobutanoate (1.15 equiv) using potassium carbonate (2.5 equiv) and potassium iodide (0.1 equiv) in acetonitrile at 70°C over 16 hours, after which the solvent is switched to DMF and the mixture is treated with palladium(II) acetate (0.05 equiv), tri(o-tolyl)phosphine (0.15 equiv), and potassium acetate (3.0 equiv) at 130°C for 24 hours to effect intramolecular direct arylation that forms the tricyclic lactam in 55–62% isolated yield after flash chromatography. Throughout this sequence, the benzyl carbamate on the pyrrolidine survives without detectable transfer hydrogenolysis despite the presence of potassium acetate at elevated temperature; however, at temperatures exceeding 135°C, a degradation product resulting from thermal N-benzyloxycarbonyl elimination is observed as an exocyclic olefin at δ 5.2–5.4 ppm by ¹H NMR in the crude reaction aliquot, so reactor jacket temperature control at 130°C ± 2°C is a documented critical process parameter. The tricyclic lactam is hydrolyzed to the free carboxylic acid with lithium hydroxide monohydrate (3.0 equiv) in THF/methanol/water (2:2:1) at 45°C, and the resulting acid is converted to the primary amide via the mixed anhydride method using isobutyl chloroformate (1.05 equiv), N-methylmorpholine (1.2 equiv), and ammonium hydroxide (28% aqueous, 5.0 equiv) at −15°C. Cbz hydrogenolysis over Pearlman's catalyst (Pd(OH)₂/C, 20 wt%) in ethanol at 40 psi hydrogen for 4 hours releases the pyrrolidine amine, which is functionalized with a pyrazole-3-carboxylic acid derivative via HATU-mediated coupling. The final crystalline API, belonging to the CFTR corrector class designated for F508del homozygous patients, is micronized and formulated with sodium lauryl sulfate, poloxamer 188, povidone K30, and croscarmellose sodium in a spray-dried dispersion with hypromellose acetate succinate (HPMCAS-MG) for amorphous solid dispersion tablets, with dissolution performed in 900 mL of 0.05 M sodium phosphate buffer pH 6.8 with 0.5% Triton X-100 at 37°C ± 0.5°C using USP <711> Apparatus II at 75 rpm, and acceptance criteria set at Q=75% at 60 minutes per FDA SUPAC-IR guidance for amorphous solid dispersions.

Epigenetic cancer therapy programs targeting the bromodomain and extraterminal (BET) family of acetyl-lysine reader proteins have evaluated imidazo[1,5-a]pyrazine-based cores where the C-1 bromine is functionalized with electron-deficient aryl groups that engage the WPF shelf of the bromodomain binding pocket through π-stacking interactions with Trp97 and Pro82 of BRD4-BD1. The intermediate is subjected to Negishi coupling with organozinc reagents prepared in situ from the corresponding aryl iodide by treatment with isopropylmagnesium chloride lithium chloride complex (Turbo Grignard, 1.3 M in THF) and zinc chloride (1.0 M in diethyl ether) at −40°C warming to room temperature, and the resulting zincate is transferred via cannula to a solution of the Cbz-pyrrolidine bromide and Pd-PEPPSI-IPr catalyst (CAS 905459-27-0) at 0.05 M concentration in THF/NMP (9:1) at 60°C. The Cbz group is preserved because the alkoxycarbonyl moiety does not coordinate zinc, but any adventitious moisture quenches the organozinc species and generates protonated arene that co-elutes with the coupling product on preparative HPLC (C18, 10 µm, 250 × 50 mm, MeCN/water with 0.1% formic acid), complicating recovery yield calculations. The coupled intermediate is next deprotected under hydrogenolysis conditions with 10% Pd/C and ammonium formate (5.0 equiv) in methanol at 50°C as the hydrogen transfer reagent, achieving Cbz removal within 45 minutes with no detectable debenzylation of the N-benzyl groups on the terminal aryl ring as verified by ¹H NMR integration of the benzylic protons at δ 4.52 ppm. The free pyrrolidine is converted to the acetamide by reaction with acetyl chloride (1.1 equiv) and triethylamine (2.5 equiv) in dichloromethane at 0°C, and the acetamide intermediate undergoes final purification by trituration from diethyl ether/hexane (1:4) to afford the API candidate. Preclinical toxicology lots are micronized to D50 2–5 µm and suspended in 0.5% (w/v) methylcellulose (400 cP nominal viscosity) with 0.2% (v/v) Tween 80 in deionized water for oral gavage administration in rodent models, with formulation stability confirmed at 4°C for 7 days by HPLC assay (≥95% recovery at day 7 relative to day 0). Resonance-stabilization energy calculations on the imidazo[1,5-a]pyrazine core indicate that bromine displacement at C-1 requires a calculated activation energy of approximately 18–22 kcal/mol for oxidative addition to Pd(0) based on DFT modeling at the B3LYP/6-31+G(d,p) level with effective core potential for palladium, but no published experimental kinetic data for this specific substrate is available in the peer-reviewed literature as of the second quarter of 2026.

An Alternative Disconnection Involving the 8-Amino Group as a Leaving Function for Urea Bond Formation

Synthetic routes to orally bioavailable toll-like receptor (TLR) 7/8 dual agonists for hepatitis B immunotherapy functionalize the 8-aminoimidazo[1,5-a]pyrazine scaffold at the amine position with a butylamine linker via reductive amination using butyraldehyde (2.0 equiv) and sodium cyanoborohydride (3.0 equiv) in methanol containing acetic acid (5% v/v) at room temperature, a transformation that preserves the C-1 bromine and the benzyl carbamate simultaneously because the imine formation is chemoselective for the primary aromatic amine over the pyrrolidine carbamate nitrogen. The resulting secondary amine is coupled with triphosgene (0.35 equiv) in the presence of triethylamine (3.0 equiv) in dichloromethane at −78°C to form the corresponding isocyanate in situ, which is immediately treated with an aminomethyl-substituted imidazoquinoline derivative to generate the urea linkage central to the TLR7/8 pharmacophore. Throughout the entire sequence from Cbz-pyrrolidine intermediate to urea formation, the C-1 bromine remains unreacted and serves as a latent handle that is only activated in the terminal chemical step, where it undergoes Sonogashira coupling with TMS-acetylene in the presence of Pd(PPh₃)₂Cl₂ (0.02 equiv), copper(I) iodide (0.04 equiv), and triethylamine as both base and solvent at 55°C, followed by TMS deprotection with tetrabutylammonium fluoride (1.0 M in THF, 1.2 equiv) to install the terminal alkyne required for copper-free strain-promoted azide-alkyne cycloaddition (SPAAC) with azide-modified targeting ligands in subsequent bioconjugation studies. Published experimental stability data for the benzyl carbamate under the cyanoborohydride reductive amination conditions indicate >95% retention after 24 hours at pH 5–6 in methanol at ambient temperature based on HPLC monitoring, whereas sodium triacetoxyborohydride causes 8–11% Cbz cleavage under identical conditions due to the formation of acetic acid that hydrolyzes the carbamate, so the cyanoborohydride reagent is specified in the batch record with a reagent identity test by FTIR before charging. The final substance, before bioconjugation, is isolated as the free base through silica gel chromatography with a dichloromethane/methanol/ammonium hydroxide (95:4.5:0.5) eluent, and residual copper is controlled below 250 ppm by treatment of the crude Sonogashira mixture with a 10% aqueous solution of N-acetylcysteine at 50°C for 1 hour, followed by extraction and column chromatography.